In this perspective, sodium-glucose cotransporter-2 inhibitors can be more advantageous for patients with MetS and RHF, given their high effectiveness in improving MetS status, reducing body weight, and decreasing glomerular filtration (24, 34, 35). Here, SLC5A2 is linked to metabolic syndrome.